Somewhere in the West Midlands, a smart pressure sensor woven into ordinary textiles is being tested on a small scale, designed to detect harm to a patient's skin before a wound forms. Elsewhere, an algorithm is being refined that could cut MRI scanning time by up to 90 per cent, freeing up machines that are among the most constrained resources in British radiology. Both projects have just received government backing through Innovate UK's Women in Innovation awards, alongside dehydration-detecting wearables aimed at older adults and RNA therapeutics targeting Parkinson's disease. On paper, this looks like exactly the kind of innovation the NHS says it needs.

What the announcement does not explain, and what almost never gets explained in these moments, is how any of it reaches a patient.

This is the tenth year of the scheme, and Innovate UK is right to point to its record: over £15 million invested since 2016, more than 260 women backed, and a shift in the proportion of successful women-led applications from one in seven to one in three. Those are genuine achievements in a funding system that has historically underserved women founders. But the scheme sits at the beginning of a pipeline, not the end of one, and the gap between a funded prototype and an adopted NHS technology has become one of the most persistent failures in British health policy, quietly acknowledged even within the same set of announcements.

Buried further down is a small but telling detail from University Hospital Southampton NHS Foundation Trust, which has completed market engagement for an outpatient administration automation project and now estimates a procurement lead time of three to six months just to move from that stage into contract. This is not a criticism of Southampton, which appears to be managing the process competently. It is a glimpse of the ordinary friction that every NHS trust faces when trying to buy something new, friction built from integrated care board sign-off, information governance checks, interoperability requirements, clinical safety cases and finance approval, layered on top of a workforce already stretched by waiting lists and winter pressures. A wearable device that could plausibly reduce hospital admissions among older adults has to pass through some version of that same process, trust by trust, with no guarantee of a favourable outcome at the end.

Health Innovation West of England's new primary care accelerator, launched with the Bristol GP federation One Care, is an implicit admission of the same problem. Its purpose is to help innovators "enter the primary care market," which is a polite way of saying that entering the primary care market is genuinely difficult even for technology with clear clinical merit. Meanwhile the Health Service Executive in Ireland has published a national framework attempting to formalise governance and implementation pathways for innovation, precisely the kind of systemic clarity that NHS trusts in England are still expected to work out locally, often trust by trust, ICB by ICB.

None of this argues against funding female founders or medical innovation more broadly. It argues that funding is the least difficult part of the problem the government claims to be solving. Ministers can announce grant rounds relatively cheaply and relatively often, because the political cost is low and the headline is straightforward. Building a procurement and adoption system capable of getting a dehydration sensor from a successful pilot into routine use across even a handful of trusts within a reasonable timeframe is harder, slower and far less photogenic, which may be exactly why it receives so much less attention.

If the current government is serious about life sciences as a growth sector and about technology easing operational pressure on the NHS, the more useful anniversary to mark would not be ten years of a grants programme, but a serious account of how many of the 260 women backed since 2016 have technology actually running inside an NHS trust today. Until that figure is known and improving, funding rounds like this one will keep generating good ideas that quietly stall at the procurement stage, one ICB at a time.